Posttranslational modification by small ubiquitin-like modifier (SUMO) conjugation regulates the subnuclear localization of several proteins; however, SUMO modification has not been directly linked to nuclear export. The ETS (E-Twenty-Six) family member TEL (ETV6) is a transcriptional repressor that can inhibit Rasdependent colony growth in soft agar and induce cellular aggregation of Ras-transformed cells. TEL is frequently disrupted by chromosomal translocations such as the t(12;21), which is associated with nearly one-fourth of pediatric B cell acute lymphoblastic leukemia. In the vast majority of t(12;21)-containing cases, the second allele of TEL is deleted, suggesting that inactivation of TEL contributes to the disease. Although TEL functions in the nucleus as a DNA-binding transcriptional repressor, it has also been detected in the cytoplasm. Here we demonstrate that TEL is actively exported from the nucleus in a leptomycin B-sensitive manner. TEL is posttranslationally modified by sumoylation at lysine 99 within a highly conserved domain (the ''pointed'' domain). Mutation of the sumo-acceptor lysine or mutations within the pointed domain that affect sumoylation impair nuclear export of TEL. Mutation of lysine 99 also results in an increase in TEL transcriptional repression, presumably because of decreased nuclear export. We propose that the ability of TEL to repress transcription and suppress growth is regulated by sumoylation and nuclear export. T he function of posttranslational modification by ligation of a small ubiquitin-like modifier (SUMO) to a target protein appears to be diverse and substrate specific. RanGAP1 was the first protein shown to be modified by addition of SUMO (1-3). Unmodified RanGAP1 is diffusely cytoplasmic, whereas sumoylation targets RanGAP1 to nuclear pore complexes. Sumoylation also directs targeted proteins such as promyelocytic leukemia and the homeodomain-interacting protein kinase 2 to distinct subnuclear domains (nuclear bodies or speckles; refs. 4 and 5). SUMO modification appears to activate the heat shock transcription factors 1 and 2 (6, 7), whereas sumoylation may negatively regulate c-JUN and c-MYB activity (8, 9). Sumoylation also affects protein stability if the modified lysine is also used for ubiquitination. Both inhibitor of NF-B␣ and murine double minute 2 are targeted for degradation by ubiquitination, but competition for the target lysine by SUMO stabilized these factors (10-12). Like ubiquitin, SUMO conjugation and deconjugation is a very dynamic process. Sumoylation studies are limited because of the rapid removal of the modification by SUMO-specific isopeptidases in cellular extracts. Thus, for each of these examples, the functional consequences of sumoylation were derived from conservative substitution of the modified lysine of the target protein.
T
he function of posttranslational modification by ligation of a small ubiquitin-like modifier (SUMO) to a target protein appears to be diverse and substrate specific. RanGAP1 was the first protein shown to be modified by addition of SUMO (1) (2) (3) . Unmodified RanGAP1 is diffusely cytoplasmic, whereas sumoylation targets RanGAP1 to nuclear pore complexes. Sumoylation also directs targeted proteins such as promyelocytic leukemia and the homeodomain-interacting protein kinase 2 to distinct subnuclear domains (nuclear bodies or speckles; refs. 4 and 5) . SUMO modification appears to activate the heat shock transcription factors 1 and 2 (6, 7), whereas sumoylation may negatively regulate c-JUN and c-MYB activity (8, 9) . Sumoylation also affects protein stability if the modified lysine is also used for ubiquitination. Both inhibitor of NF-B␣ and murine double minute 2 are targeted for degradation by ubiquitination, but competition for the target lysine by SUMO stabilized these factors (10) (11) (12) . Like ubiquitin, SUMO conjugation and deconjugation is a very dynamic process. Sumoylation studies are limited because of the rapid removal of the modification by SUMO-specific isopeptidases in cellular extracts. Thus, for each of these examples, the functional consequences of sumoylation were derived from conservative substitution of the modified lysine of the target protein.
Like ubiquitination, sumoylation is a three-step process involving an E1-activating enzyme heterodimer Aos͞Uba2, the E2-conjugating enzyme Ubc9 and substrate-specific E3 ligases (for recent reviews, see refs. 13 and 14) . The nucleoporin RanBP2͞Nup358 and the protein inhibitors of activated signal transducer and activator of transcription family represent two types of E3 ligases (15) (16) (17) (18) (19) . Sumoylation forms an isopeptide bond between the C-terminal carboxyl group of SUMO and the -amino group of a lysine residue in the target protein. Three SUMO family members have been identified (SUMO1, SUMO2, and SUMO3; ref. 20) . SUMO2 and SUMO3 are 95% identical and 40-50% homologous to SUMO1, suggesting that SUMO2 and SUMO3 have similar functions. Several mammalian SUMO isopeptidases have been identified, including SENP1, Smt3IP1, SUSP1, and Smt3IP2͞SENP2 (21) (22) (23) (24) . SENP2 and RanBP2 localize to the nuclear pore complexes, suggesting that SUMO can be added and͞or removed as proteins pass between the cytoplasm and nucleus (25, 26) .
TEL (also know as ETV6) is an E-Twenty-Six (ETS)-family transcriptional repressor that is modified by sumoylation (27, 28) . TEL is a frequent target of chromosomal translocations in both myeloid and lymphoid leukemias, which fuse the N-terminal pointed domain [PNT, also called helix-loop-helix or sterile ␣ motif (SAM)] to tyrosine kinases including plateletderived growth factor-␤, c-ABL, and Janus kinase 2 (29, 30) . However, the most frequent chromosomal translocation involving TEL is the t(12;21), which fuses the N terminus of TEL to the acute myeloid leukemia (AML)1 transcription factor (also called RUNX1; for comprehensive reviews, see refs. 29 and 31). The t(12;21) is the most common genetic rearrangement found in childhood pre-B cell acute lymphoblastic leukemia. In the majority of t(12;21)-containing acute lymphoblastic leukemia, the second allele of TEL is deleted, suggesting that TEL is a tumor suppressor.
Whereas oncogenic ETS factors are mediators of Ras signals, TEL inhibits Ras-dependent transformation of NIH 3T3 cells (32) (33) (34) . TEL may oppose the transactivation functions of oncogenic ETS factors by actively repressing ETS factor target genes through the recruitment of corepressors such as mSin3A, nuclear hormone corepressor, and histone deacetylase-3 (35) (36) (37) (38) . When expressed in Ras-transformed NIH 3T3 cells, TEL induced cellular aggregation, directly implicating TEL in cell adhesion (32, 34) . Cellular aggregation correlated with repression of stromelysin-1, which is involved in extracellular-matrix remodeling (34) . A histone deacetylase inhibitor not only impaired TEL-dependent transcriptional repression of the stromelysin-1 promoter, but biologically inactivated TEL in cellular aggregation assays (34, 36) .
The PNT domain of TEL is a focal point for regulation of TEL because this domain mediates associations with mSin3A, homodimerization, and binding to other ETS factors (39) (40) (41) (42) . In addition, the SUMO-conjugating enzyme Ubc9 binds to the PNT domain and ligates SUMO to lysine 99 (27, 28) . Sumoylation appears to target TEL to specific nuclear speckles in a subset of the cell population (28) . TEL is a predominately nuclear phosphoprotein that represses transcription by directly binding to the promoters of target genes. However, when TEL was expressed in fibroblasts, it was both nuclear and cytoplasmic (32) . Here we show that TEL is actively exported from the nucleus. TEL proteins with mutations that disrupt the PNT domain accumulate in the nucleus, suggesting that this domain mediates nuclear export. The highly conservative change of lysine 99 to arginine, within the PNT domain, blocks SUMO modification and caused a dramatic accumulation of TEL in the nucleus, implying that sumoylation of TEL regulates the nuclear export of this tumor suppressor.
Experimental Procedures
Cells and Biological Assays. COS-7 and HeLa cells were obtained from the American Type Culture Collection. COS-7, 293T, and HeLa cells were grown in DMEM with 10% FBS. Rastransformed and nontransformed NIH 3T3 cells were grown in DMEM with 10% calf serum. Retroviral infections of Rastransformed 3T3 cells with pBabePuro retroviruses, soft agar colony-formation assays, and luciferase assays were performed as described (34) .
Plasmids. pBabePuro, pCMV-TEL, and pCMV-TEL͞AML were as described (43) . pBabePuro-TEL, pCMV-TEL⌬P (residues 40-104 deleted), ⌬122-268, ⌬266-335, ⌬ETS (residues 374-385 deleted), and ⌬Pϩ⌬266 were as described (note ⌬266-335 has an additional BglII site at the deletion site and was originally incorrectly called ⌬268-333; refs. 34 and 36). Hemagglutinin (HA)-tagged TEL constructs were made by amplifying fulllength TEL or deletions by using PCR and KpnI-linked 5Ј primers and the XbaI-linked 3Ј primer (5Ј-atctctagatcagcattcatcttcttg-3Ј) and ligated into a modified pCMV5 vector that has the HA tag inserted after the EcoRI site. Point mutations were made by using the QuikChange site-directed mutagenesis kit (Stratagene), and the sequence was confirmed. The GFP-SUMO1 and GFP-SUMO2͞3 were as described (20, 44) .
Immunoprecipitation and Immunoblot Analysis. Immunoprecipitation and immunoblot analysis were performed as described (34, 35) except for the addition of 20 M N-ethylmaleimide. Antibodies used for immunoprecipitation were anti-mSin3A or anti-HA tag. Polyclonal antibodies made against mSin3A, HA-tag, and c-Raf were obtained from Santa Cruz Biotechnology, and monoclonal anti-HA and anti-c-myc were from Covance (Berkeley, CA). Antibodies against C-terminal and N-terminal TEL were as described (34, 35) . Cell fractionation was performed as described (45) .
Immunofluorescence. Cells were transfected by using Superfect (Qiagen, Chatsworth, CA) according to the manufacturer's instructions. Leptomycin B (LMB), N-ethylmaleimide, normal goat serum, and Hoechst no. 33258 were obtained from Sigma. The cells were fixed in 3.7% formaldehyde͞PBS, permeabilized in 0.1% Nonidet P-40͞PBS, and blocked in 10% normal goat serum͞PBS for 30 min. Cells were incubated with primary antibodies (diluted in 10% normal goat serum͞PBS) for 60 min. Anti-TEL and anti-HA were used at a 1:1,000 dilution or a polyclonal antibody against the HA tag at a 1:250 dilution. Cells were then incubated for 60 min with the appropriate Alexa488-conjugated secondary antibodies. Anti-mouse and anti-rabbit Alexa488 or Alexa546 were obtained from Molecular Probes. Cells were incubated with 5 ng͞ml Hoechst dye for 5 min to visualize DNA. Cells were analyzed on a Zeiss Axiophot microscope by using Zeiss 40 ϫ 1.4 oil immersion objectives. For protein localization scoring, at least 200 cells for each condition were scored, with results presented as percentage of counted cells.
Results
Endogenous TEL Is Located in Both the Cytoplasm and Nucleus. TEL functions in the nucleus as a transcriptional repressor (35, 37, 43, 46 ), yet, when TEL was expressed in NIH 3T3 cells, it was detected in both the cytoplasm and nucleus (32) . Therefore, we examined the localization of endogenous TEL by fractionation of NIH 3T3 cells (Fig. 1A) . We found a significant proportion of the endogenous TEL was cytoplasmic. In this experiment, the level of cytoplasmic TEL was Ͼ50%, although the amount varied from 30% to 70% between experiments ( Fig. 1 A) . In addition, the cytoplasmic form of TEL appeared to include a hyperphosphorylated form (see arrowheads, Fig. 1 A) . A third form that is derived from internal translational initiation from methionine 43 (TEL-43; ref. 47 ) was consistently more nuclear in its localization ( Fig. 1 A) . Detection of either nuclear mSin3A or cytoplasmic c-Raf was used as a control. SUMO-modified TEL represents only a small percentage of the total TEL protein. Whether this situation exists because only a small percentage of TEL is targeted for SUMO conjugation or whether SUMO is rapidly removed by SUMO-specific protease activity is unclear. To detect sumoylated TEL, we expressed epitope-tagged TEL (HA-TEL) in COS cells. As expected, fractionation of the HA-TEL-transfected COS cells revealed that the SUMO modified form was nuclear (data not shown; ref. 28) .
Cell fractionation determines the relative distribution of TEL in a population of cells. To examine the distribution of TEL in single cells, we performed immunofluorescence with a Cterminal TEL antibody. Endogenous TEL was detected in both the cytoplasm and the nucleus of most cells. However, in a limited number of cells, TEL appeared to be either excluded from the nucleus (Fig. 1B , see arrow in Center) or primarily nuclear (Fig. 1B Left) . Although not representative of the population, Fig. 1B Right shows a cluster of cells in which TEL is mostly cytoplasmic. Similar staining of endogenous TEL was seen with an N-terminal TEL antibody that recognizes fulllength TEL but not TEL-43 (data not shown).
LMB Inhibits TEL Export. The observation that TEL can be detected in the cytoplasm or nucleus suggested that either a portion of TEL is retained in the cytoplasm or that TEL is exported from the nucleus. Many nuclear-cytoplasmic shuttling proteins depend on the nuclear export receptor Crm-1 for nuclear exit (48) , and Crm-1 is inactivated by LMB treatment (49, 50) . Therefore, we transiently expressed epitope-tagged (HA-tagged) TEL in NIH 3T3 cells and determined the cellular localization of TEL in the absence or presence of LMB. In the absence of LMB, HA-TEL appeared to localize predominantly to the cytoplasm in Ϸ60% of the cells (Fig. 2) . In the remaining cells, TEL was more nuclear or equally distributed between the two compartments. Similar cytoplasmic staining of HA-TEL was observed in telomerase-immortalized human foreskin fibroblasts, HeLa, and COS-7 cells (data not shown). LMB treatment of the transfected NIH 3T3 cells resulted in a decrease in the number of cells displaying cytoplasmic localization of TEL (Ϸ30% cells) with an increase in the number of cells displaying predominantly nuclear TEL. These results imply that TEL is actively exported from the nucleus in a Crm-1-dependent manner.
TEL Pointed Domain Is Required for Cytoplasmic Localization. Mutations within the DNA-binding domain of TEL resulted in the loss of the nuclear localization of TEL, whereas deletion of residues 53-116 in the PNT domain resulted in both cytoplasmic and nuclear localization of TEL (32) . The PNT domain is important for association with mSin3A, and it mediates homodimerization. The central domain of TEL that lies between the pointed domain and the C-terminal ETS DNA-binding domain interacts with both histone deacetylase-3 and nuclear hormone corepressor (36) . Therefore, we tested mutants of TEL to define whether association with nuclear proteins or DNA affects the nuclear accumulation of TEL. NIH 3T3 cells were transiently transfected with various HA-tagged TEL deletion mutants (Fig. 3A) , and the localization was determined for each mutant protein (Fig. 3B) . We found that deletion of residues 40-104 (⌬P) increased nuclear accumulation. Deletion of the middle region of TEL (⌬122-268) or central domain, in which histone deacetylase-3͞ nuclear corepressor binds (⌬266-335), behaved similarly to wild-type TEL in that the majority of the cells displayed cytoplasmic localization of TEL. Disruption of the DNA-binding domain (⌬ETS) showed almost no nuclear localization possibly because of the lack of binding to DNA. Therefore, the PNT domain, which is sufficient for mSin3A association and homodimerization, contributes to the nuclear export of TEL.
To confirm that the N terminus of TEL, including the PNT domain, is sufficient to direct nuclear export, we took advantage of the t(12;21) fusion protein, which fuses the N-terminal 336 residues of TEL to nearly all of the AML1 transcription factor. AML1 is exclusively nuclear and associates with the nuclear matrix (51) . HA epitope-tagged AML1 and TEL-AML1 were transfected into COS-7 cells and their localization was determined by immunof luorescence. As expected, AML1 was predominantly localized to the nucleus (Fig. 3C) . By contrast, TEL-AML1 was both nuclear and cytoplasmic (Fig. 3C) , indicating that TEL encodes sequences that are sufficient to relocalize AML1 to the cytoplasm.
Point Mutations in the Pointed Domain of TEL Inhibit Nuclear Export.
Because the pointed domain of TEL mediates dimerization, we hypothesized that dimerization contributes to the nuclear export of TEL. This could be a regulatory signal, because high levels of nuclear TEL would promote dimerization and nuclear export. Structural analysis of the TEL pointed domain (also known as the SAM domain) revealed a helical head-to-tail polymer with two binding surfaces: the mid-loop and end-helix surfaces (52, 53) . A point mutation in the mid-loop surface (A93D) creates a SAM domain that fails to homodimerize but can heterodimerize with the wild-type TEL-SAM domain (sequences in Fig. 4A ; ref. 53) . By contrast, a substitution in the end-helix surface (V112E) only partially impairs dimerization in that it retains the ability to weakly self-associate and strongly heterodimerize with the wildtype TEL-SAM domain (52, 53) . Combining the two mutations resulted in failure to either homo-or heterodimerize (52, 53) . After placing the point mutations within the context of fulllength TEL, we obtained similar results in that the single point mutants still heterodimerized with wild-type TEL, but the double mutant failed to homo-or heterodimerize (data not shown). When these TEL mutants were expressed and localized by indirect immunofluorescence, all three mutants were predominantly nuclear in contrast to wild-type TEL (Fig. 4B) .
The nuclear localization of the dimerization mutants may suggest that homodimerization is required for nuclear export. However, despite the nuclear accumulation of these mutants, they were impaired in repressing transcription in reporter assays (Fig. 4C) . TEL(A93D) was inactive, whereas TEL(V112E), while still active at higher levels of input expression plasmid, was impaired in its ability to repress the stromelysin-1 promoter. Therefore, we tested whether these mutants were able to associate with mSin3A. As predicted from the transcriptional analysis, TEL(A93D) failed to associate with mSin3A, whereas TEL(V112E) was impaired for binding to mSin3A (data not shown). Thus, the A93D substitution disrupts both dimerization and corepressor binding, whereas V112E is a less severe mutation when placed in the context of full-length TEL. However, both mutations affect nuclear export. While monitoring the expression of the dimerization mutants, we noted that these mutants were not modified by sumoylation. Coexpression of wild-type TEL or these mutants with a GFPlinked SUMO1 (data not shown) or GFP-SUMO2 in COS-7 cells confirmed that the point mutants were not modified by the addition of GFP-SUMO2 ( Fig. 4D ; single arrowhead denotes SUMO-TEL; double arrowheads denote GFP-SUMO-TEL; note that the addition of GFP to SUMO2 reduces the mobility of SUMO-TEL). These results suggested that either wild-type levels of dimerization are necessary for SUMO conjugation or the structure of the TEL mutants is altered so that SUMO conjugation could not occur.
Sumoylation Contributes to the Nuclear Export of TEL.
Because TEL(V112E) can still weakly self-associate (52) and retained partial transcriptional function but was not efficiently sumoylated, it appeared that the failure of this mutant to be exported from the nucleus was because of a lack of sumoylation. To directly test this hypothesis, we tested whether the highly conservative substitution of arginine for lysine at residue 99, which is the major site for SUMO conjugation (28) , would affect the nuclear export of TEL. When the cellular localization of TEL(K99R) was determined by indirect immunofluorescence in both stably infected or transiently transfected NIH 3T3 cells, it was predominantly nuclear (Fig. 5 A and B) .
To ensure that the K99R mutation did not disrupt the structure of the pointed domain, we tested TEL(K99R) in assays that depend on a functional pointed domain. Lysine 99 lies between the two dimerization surfaces of the pointed domain, and, as expected from the structural predictions, TEL(K99R) retained the ability to homo-and heterodimerize (data not shown). This finding suggested that the K99R mutation did not alter the structure of the pointed domain, and we confirmed that TEL(K99R) was still able to bind to mSin3A (Fig. 5C ). In addition, TEL(K99R) was as efficient or better than wild-type TEL at inhibiting colony formation in soft agar by Rastransformed NIH 3T3 cells (Fig. 5D) . In more quantitative assays, TEL(K99R) was a better transcriptional repressor than wild-type TEL at equal levels of input expression plasmid (Fig.  5E ). Immunoblot analyses of the lysates confirmed that the same level of TEL proteins was expressed at each concentration for each transfected construct (data not shown). Thus, the lack of nuclear export of TEL(K99R) functionally correlates with its greater ability to repress transcription and suggests that SUMO modification contributes to the nuclear export of TEL.
Discussion
SUMO modification of nuclear proteins is now recognized as a prevalent posttranslational modification. However, the functional consequences of this modification are known for only a few proteins. For instance, mutational analysis of the promyelocytic leukemia tumor suppressor indicates that sumoylation directs promyelocytic leukemia into nuclear promyelocytic leukemia oncogenic domains (4, 54, 55). Our data suggest an additional function for SUMO conjugation: regulation of nuclear export. TEL is exported from the nucleus (Fig. 1) , and a single, highly conservative mutation impairs both SUMO modification and nuclear export (Figs. 4 and 5 ). This mutant form of TEL is capable of carrying out all of the known functions of wild-type TEL; moreover, it is hyperactive, owing to its lack of nuclear export (Fig. 5) . Whereas many proteins that are exported from the nucleus are degraded in the cytoplasm, TEL appears to be a very stable protein (L.D.W. and S.W.H., unpublished data). Once TEL is exported, it may be retained in the cytoplasm or quickly reimported to the nucleus as needed. Therefore, nuclear export of TEL may be an efficient mechanism to regulate this important growth suppressor.
In yeast, temperature-sensitive mutants of the SUMO conjugation pathway block nuclear import of proteins containing a classic nuclear localization signal (56) . However, the block in import was attributed to the failure of the importin-␣ subunit Srp1 to be recycled by export from the nucleus (56) . Although the failure to export Srp1 is likely indirect, because a SUMOmodified form of Srp1 was not detected, our data indicate that the lack of sumoylation directly impairs the nuclear export of TEL. Coupled with the genetic study of general sumoylation in yeast, we hypothesize that sumoylation may be a more general mechanism for regulating nuclear export.
It is notable that several ETS family members such as NET and YAN are regulated by nuclear export, and both NET and YAN contain putative SUMO acceptor sites. YAN is the closest Drosophila homolog to TEL, and, like TEL, YAN-mediated repression is regulated by nuclear export (57) . Sumoylation of YAN has yet to be addressed, but, phosphorylation on multiple residues appears to redirect YAN from the nucleus to the cytoplasm, thereby relieving repression (57, 58) . In several examples, phosphorylation regulates SUMO modification (4, 8, 59, 60) , and in our initial cell-fractionation experiments we noted that the hyperphosphorylated forms of full-length TEL were predominantly cytoplasmic (Fig. 1) . In this regard, we note that Ϸ5-15% of the cells had cytoplasmic localization of TEL(K99R) (Fig. 5 ). Thus, it is possible that phosphorylation of TEL can also contribute to its nuclear export. Further analysis of other ETS factors will be required to determine whether sumoylation plays a more widespread role in nuclear export and to define whether phosphorylation regulates sumoylation and͞or nuclear export of TEL.
Because of the labile nature of SUMO modification, it is difficult to directly assess how sumoylation of TEL might mediate nuclear export. K99 lies between two dimerization interfaces (see Fig. 4 and refs. 52 and 53), so SUMO conjugation may alter the conformation of TEL to expose a nuclear export signal or create a binding site for an export factor. TEL contains three weak nuclear export signals based on the LMB-sensitive export motif (LX (1) (2) (3) LX (1) (2) (3) LXL). Mutation of the leucines within the first two of these sequences yielded no effect on TEL nuclear export, but mutations in the third putative nuclear export signal (residues 113-121) did block cytoplasmic localization (L.D.W., unpublished data). However, this motif lies within the second dimerization interface of the pointed domain, and this TEL mutant failed to dimerize and was not sumoylated. We were therefore unable to unambiguously identify a nuclear export signal. Alternatively, TEL has been detected in subnuclear ''speckles'' in a subset of transfected cells, whereas the sumodeficient mutant TEL(K99R) is excluded from these domains (28) . These speckles were not readily apparent in the majority of our experiments, but were observed occasionally. It is possible that these speckles represent ''loading docks'' for nuclear export, or they may be an alternative functional domain unrelated to nuclear export. Regardless of the precise mechanism, when the N terminus of TEL is added to AML1 by the t(12;21), it caused cytoplasmic localization of the fusion protein, indicating that TEL residues 1-336 contain a region that mediates nuclear export.
Similarly to TEL, TEL͞AML1 is also sumoylated (28) , and mutation of the SUMO target lysine (Lys-99) in TEL͞AML1 results in increased nuclear retention (L.D.W., unpublished data). The portion of TEL that is found fused to AML1 (RUNX1) is also fused to tyrosine kinases (TEL͞platelet-derived growth factor receptor-␤, TEL͞Janus kinase 2, and TEL͞ABL) in chronic myelogenous leukemia and AML (29, 30) . Although most of these kinases are normally cytoplasmic, it will be of interest to determine whether mutation of K99 within these tyrosine kinase fusion proteins can cause inappropriate nuclear localization and impair the transformation ability of these fusion proteins.
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